Bristol Myers Squibb Net Income 2010-2022 | BMY

Bristol Myers Squibb annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Bristol Myers Squibb net income for the quarter ending September 30, 2022 was $1.606B, a 3.88% increase year-over-year.
  • Bristol Myers Squibb net income for the twelve months ending September 30, 2022 was $6.677B, a 223.53% decline year-over-year.
  • Bristol Myers Squibb annual net income for 2021 was $6.994B, a 177.58% decline from 2020.
  • Bristol Myers Squibb annual net income for 2020 was $-9.015B, a 362.14% decline from 2019.
  • Bristol Myers Squibb annual net income for 2019 was $3.439B, a 30.1% decline from 2018.
Bristol Myers Squibb Annual Net Income
(Millions of US $)
2021 $6,994
2020 $-9,015
2019 $3,439
2018 $4,920
2017 $1,007
2016 $4,457
2015 $1,565
2014 $2,004
2013 $2,563
2012 $1,959
2011 $3,701
2010 $3,090
2009 $10,594
Bristol Myers Squibb Quarterly Net Income
(Millions of US $)
2022-09-30 $1,606
2022-06-30 $1,421
2022-03-31 $1,278
2021-12-31 $2,372
2021-09-30 $1,546
2021-06-30 $1,055
2021-03-31 $2,021
2020-12-31 $-10,027
2020-09-30 $1,872
2020-06-30 $-85
2020-03-31 $-775
2019-12-31 $-1,056
2019-09-30 $1,353
2019-06-30 $1,432
2019-03-31 $1,710
2018-12-31 $1,160
2018-09-30 $1,901
2018-06-30 $373
2018-03-31 $1,486
2017-12-31 $-2,328
2017-09-30 $845
2017-06-30 $916
2017-03-31 $1,574
2016-12-31 $894
2016-09-30 $1,202
2016-06-30 $1,166
2016-03-31 $1,195
2015-12-31 $-197
2015-09-30 $706
2015-06-30 $-130
2015-03-31 $1,186
2014-12-31 $13
2014-09-30 $721
2014-06-30 $333
2014-03-31 $937
2013-12-31 $726
2013-09-30 $692
2013-06-30 $536
2013-03-31 $609
2012-12-31 $924
2012-09-30 $-711
2012-06-30 $645
2012-03-31 $1,101
2011-12-31 $850
2011-09-30 $967
2011-06-30 $900
2011-03-31 $984
2010-12-31 $471
2010-09-30 $949
2010-06-30 $927
2010-03-31 $743
2009-12-31 $8,007
2009-09-30 $966
2009-06-30 $983
2009-03-31 $638
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $155.188B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00